We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Asterand Announces Collaborative Agreement to Characterize Antibodies
News

Asterand Announces Collaborative Agreement to Characterize Antibodies

Asterand Announces Collaborative Agreement to Characterize Antibodies
News

Asterand Announces Collaborative Agreement to Characterize Antibodies

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Asterand Announces Collaborative Agreement to Characterize Antibodies"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Asterand plc has announces that it has entered into a collaborative agreement with Abcam plc. Asterand will undertake the validation and characterization of a selected group of Abcam antibodies for immuno-histochemistry applications using Asterand’s PhaseZERO® Human Tissue Services platform.

Through this agreement, Asterand will utilize its proprietary Target Evaluator™ database to pinpoint the expression patterns of selected antibody targets across a panel of human tissue types. The database consists of quantitative human gene expression profiles that chart the expression topography of more than 2,000 commercially relevant gene transcripts across a panel of 72 human tissues.

Once appropriate tissue has been selected for testing, Asterand will validate the Abcam antibodies using immuno-histochemical detection to determine the optimal dilutions and concentrations of the antibodies for use with human tissue. The resulting data and photomicrographs will be incorporated into Abcam’s literature and technical support documentation for each antibody tested.

All services provided through this agreement are part of Asterand’s standard PhaseZERO® human tissue services platform. The tested antibodies will be sold through Abcam’s online catalogue. Terms of the agreement were not disclosed.
Advertisement